共 50 条
- [41] Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Hammers, Hans J.Plimack, Elizabeth R.Infante, Jeffrey R.Ernstoff, Marc S.Rini, Brian I.McDermott, David F.Razak, Albiruni R. A.Pal, Sumanta KumarVoss, Martin HennerSharma, PadmaneeKollmannsberger, Christian K.Heng, Daniel Yick ChinSpratlin, Jennifer L.Shen, YunKurland, John F.Gagnier, PaulAmin, Asim
- [42] A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell CarcinomaMEDICINA-LITHUANIA, 2022, 58 (03):Studentova, HanaZemankova, AnezkaSpisarova, MartinaSkanderova, DanielaTudos, ZbynekMelichar, BohuslavStudent, Vladimir, Jr.
- [43] Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in placeEUROPEAN UROLOGY, 2024, 85 : S1859 - S1860Jurascheck, L.Van de Putte, Fransen E.Van den Brink, L.Van der Mijn, J. C.Wilgenhof, S.Van Thienen, J. V.Haanen, J. B. A. G.Boleti, E.Powles, T.Zondervan, P. J.Graafland, N. M.Bex, A.
- [44] Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumabFRONTIERS IN ONCOLOGY, 2022, 12Kim, Jwa HoonKim, Gi HwanRyu, Yeon-MiKim, Sang-YeobKim, Hyung-DonYoon, Shin KyoCho, Yong MeeLee, Jae Lyun
- [45] Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and NivolumabCLINICAL GENITOURINARY CANCER, 2024, 22 (06)Ornstein, Moshe C.George, LaethWei, WeiDiaz-Montero, C. MarcelaRayman, PatMartin, AllisonBasu, ArnabBeckermann, Kathryn E.Nizam, AmandaWee, Christopher E.Gilligan, Timothy D.Gupta, ShilpaRini, Brian I.
- [46] The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) plus ipilimumab (ipi).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 545 - 545Grewal, KabirChauhan, Pankaj KumarMukhida, Sagar S.Tannir, Nizar M.Venkatesh, NehaShah, Amishi YogeshZurita, Amado J.Johns, AndrewCampbell, Matthew T.Goswami, SangeetaGao, JianjunJonasch, EricMcquade, Jennifer LeighAlhalabi, OmarMsaouel, PavlosHahn, Andrew Warren
- [47] The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapyINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1019 - 1026Numakura, KazuyukiSekine, YuyaOsawa, TakahiroNaito, SeiTokairin, OjiroMuto, YuminaSobu, RyutaKobayashi, MizukiSasagawa, HajimeYamamoto, RyoheiNara, TaketoshiSaito, MitsuruNarita, ShintaroAkashi, HideoTsuchiya, NorihikoShinohara, NobuoHabuchi, Tomonori
- [48] Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinomaJAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (04) : 646 - 653Tachibana, HidekazuKondo, TsunenoriIshihara, HirokiFukuda, HironoriYoshida, KazuhikoTakagi, ToshioIzuka, JunpeiKobayashi, HirohitoTanabe, Kazunari
- [49] Nivolumab plus ipilimumab in advanced renal-cell carcinomaLANCET ONCOLOGY, 2018, 19 (05): : E232 - E232Gunjur, Ashray
- [50] Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma PatientsCLINICAL GENITOURINARY CANCER, 2022, 20 (03) : 210 - 218Thana, MyuranBasappa, Naveen S.Ghosh, SunitaKollmannsberger, Christian K.Heng, Daniel Y. C.Hansen, Aaron R.Graham, JefferySoulieres, DenisReaume, Martin NeilLalani, Aly-Khan A.Castonguay, VincentBjarnason, Georg A.Patenaude, FrancoisBreau, Rodney H.Pouliot, FredericKapoor, AnilWood, Lori A.